Group 1 - The report highlights that the company plans to issue convertible bonds to raise up to 878 million RMB for investment in new projects, including a 5000 tons/year vitamin K3 and 74,000 tons/year chromium green project, and a 500,000 tons/year sulfuric acid and 50,000 tons/year chromium powder project [3][5] - The innovative "vitamin K3 co-production chromium green" process is expected to break the production bottleneck of chromium green, utilizing chromium-containing waste from vitamin K3 production to create high-quality chromium green, thus enhancing environmental performance and operational results [5][6] - The company has successfully acquired land for the new project in Chongqing, with a total investment of approximately 3 billion RMB, which will significantly drive long-term growth [7][8] Group 2 - The report indicates that the chromium market is experiencing a bullish cycle, with the average price of metallic chromium rising from 67,500 RMB/ton to 82,000 RMB/ton, and chromium oxide green prices increasing from 29,500 RMB/ton to 36,500 RMB/ton [9][10] - The downstream demand for chromium is expected to grow due to the increasing needs in high-temperature alloys used in military and civilian aircraft, gas turbines, and other high-end equipment, which will further boost the market demand for chromium and its raw materials [5][10] - The company is projected to benefit from the chromium market cycle, with revenue forecasts for 2025, 2026, and 2027 estimated at 43.63 billion RMB, 66.42 billion RMB, and 72.52 billion RMB, respectively, alongside net profits of 6.04 billion RMB, 11.96 billion RMB, and 13.70 billion RMB [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a significant year-on-year increase in net profit for 2025, with estimates ranging from 96 million to 110 million yuan, representing a growth of 50.60% to 72.56%. The adjusted net profit forecast for 2025-2027 is 110 million, 167 million, and 221 million yuan respectively, with corresponding EPS of 1.31, 1.98, and 2.63 yuan. The current stock price corresponds to a PE ratio of 25.2, 16.6, and 12.5 times for the years 2025, 2026, and 2027 [4][8] Summary by Relevant Sections Financial Performance - The company forecasts a revenue of 1.035 billion yuan for 2025, with a year-on-year growth of 13.7%. The net profit margin is expected to improve to 10.6% in 2025, with a projected net profit of 110 million yuan, reflecting a 72.0% increase compared to the previous year [8][11] Potassium Salt Industry - The domestic potassium carbonate industry is characterized by an oligopoly with limited players and no significant expansion plans in the short term. The company, as a leading domestic producer, has an annual production capacity of 85,000 tons of light potassium carbonate. The anticipated integration of competitors facing financial difficulties may further enhance profitability in the industry as demand steadily increases [5] Veterinary Medicine Sector - The global market demand for Amprolium hydrochloride is estimated to be between 1,200 to 1,500 tons annually, with the company holding a production capacity of 600 tons per year. A planned expansion project is expected to increase capacity to 800 tons per year by June 2026. Geopolitical tensions in the Middle East may disrupt supply from competitors, allowing the company to benefit from increased market share [6] PEEK Project - The company plans to invest 193 million yuan to establish a production line for 2,000 tons of PEEK and key intermediates. This project aims to create a complete industrial chain from fluorobenzene to fluoroketone and PEEK, leveraging technical support from renowned universities. This investment is expected to open up long-term growth opportunities for the company [7]

Market Overview - The Shanghai Composite Index has returned to 4000 points with a rise of 1.38% on January 5, while the Shenzhen Component Index increased by 2.24% and the ChiNext Index rose by 2.85% [1] High-Performing Stocks - Fenglong Co., Ltd. achieved a 10% increase, marking its seventh consecutive trading day of gains [4] - Delixi Co., Ltd. saw a 10.03% rise, with four gains over eight days [4] - Leike Defense experienced a 10.04% increase, marking its fourth consecutive gain [4] - China Satellite Communications and Beidou Star achieved a 9.99% increase, with both stocks gaining for three days [4] - Other notable stocks include Nansheng Co., Ltd. and Youbang Ceiling, both with three consecutive gains [3][4] Trading Activity - The top three net buying stocks on the Dragon and Tiger list were Aerospace Electromechanical, Wuzhou New Spring, and Puran Co., with net purchases of 419 million, 284 million, and 272 million respectively [5] - The top three net selling stocks were BlueFocus, Zhongchao Holdings, and Luxin Investment, with net sales of 422 million, 414 million, and 343 million respectively [7] Company Highlights - Aerospace Electromechanical is involved in military supply projects and has resumed sales of photovoltaic components in Europe, while also expanding production capacity [13] - Wuzhou New Spring has received approval for a 1 billion yuan private placement to fund the development of humanoid robots and core components for intelligent driving [16] - Tianji Co., Ltd. has a lithium hexafluorophosphate production capacity of 37,000 tons per year and is fully sold out, with plans for further expansion [19] Institutional Activity - Institutional net buying was significant for stocks like BlueFocus and Haike New Source, with net purchases of 186 million and 117 million respectively [8][20] - Conversely, institutional net selling was notable for Wuzhou New Spring and Zhongchao Holdings, with net sales of 221 million and 220 million respectively [9][24]

IPO Overview - As of January 4, 2026, there are 342 companies in the IPO queue, with 23 on the Shanghai Main Board, 46 on the Sci-Tech Innovation Board, 21 on the Shenzhen Main Board, 44 on the Growth Enterprise Market, and 208 on the Beijing Stock Exchange [1][2]. Newly Listed Companies - Five companies were newly listed between December 29, 2025, and January 4, 2026, including Inner Mongolia Shuangxin Environmental Materials Co., Ltd., Shanghai Yufan Environmental Technology Co., Ltd., Qiangyi Semiconductor (Suzhou) Co., Ltd., Suzhou Xinguangyi Electronics Co., Ltd., and Hengtong Communication Technology (Shenzhen) Co., Ltd. [3][4]. Stock Performance of Newly Listed Companies - Inner Mongolia Shuangxin Environmental Materials Co., Ltd. closed at 19.68 CNY per share, with a rise of 187.30% and a trading volume of 30.45 billion CNY [5]. - Shanghai Yufan Environmental Technology Co., Ltd. closed at 50.01 CNY per share, with a rise of 124.36% and a trading volume of 9.41 billion CNY [5]. - Qiangyi Semiconductor (Suzhou) Co., Ltd. closed at 226.01 CNY per share, with a rise of 165.61% and a trading volume of 43.45 billion CNY [6]. - Suzhou Xinguangyi Electronics Co., Ltd. closed at 71.32 CNY per share, with a rise of 225.22% and a trading volume of 17.41 billion CNY [6]. - Hengtong Communication Technology (Shenzhen) Co., Ltd. closed at 309.00 CNY per share, with a rise of 878.16% and a trading volume of 36.48 billion CNY [7]. New Counseling Record Companies - A total of 35 companies were newly recorded for counseling between December 29, 2025, and January 4, 2026, including Shenzhen Chenzhuo Technology Co., Ltd., Beijing Bimai Sports Co., Ltd., and others [8][9]. Companies Approved for Registration - Five companies received registration approval during the same period, including Dalian Meidele Industrial Automation Co., Ltd., Zhejiang Haisheng Medical Devices Co., Ltd., and others [22][23]. Companies with Terminated Reviews - Dalian Ruike Technology Co., Ltd. has terminated its IPO review [26][27].

Market Overview - The chemical raw materials sector increased by 0.52% compared to the previous trading day, with Dayang Biological leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Top Performers - Dayang Biological (stock code: 003017) closed at 32.85, with a rise of 10.01% and a trading volume of 89,600 shares, amounting to a transaction value of 288 million [1] - Zhenhua Co., Ltd. (stock code: 603067) also saw a significant increase of 10.00%, closing at 31.69 with a trading volume of 283,700 shares [1] - Aokai Co., Ltd. (stock code: 300082) rose by 9.39%, closing at 10.83 with a trading volume of 517,000 shares [1] Underperformers - Jiaxian Co., Ltd. (stock code: 920489) experienced the largest decline, falling by 10.33% to close at 16.14, with a trading volume of 92,800 shares [2] - Huatai (stock code: 001217) decreased by 5.76%, closing at 13.10 with a trading volume of 246,900 shares [2] - Boyuan Chemical (stock code: 000683) saw a decline of 1.88%, closing at 7.30 with a trading volume of 822,400 shares [2] Capital Flow - The chemical raw materials sector saw a net inflow of 318 million from main funds, while retail investors experienced a net outflow of 325 million [2][3] - Dayang Biological attracted a net inflow of 90.33 million from main funds, while retail investors had a net outflow of 52.60 million [3] - Zhenhua Co., Ltd. had a net inflow of 25.60 million from main funds, with retail investors showing a net outflow of 13.36 million [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook based on the anticipated benefits from the chromium salt market cycle [14]. Core Insights - The company plans to issue convertible bonds to raise up to RMB 878 million for investment in new projects, including a 50,000 tons/year chromium powder project and a 7.4 million tons/year chromium green project, which will enhance production capacity and optimize processes [6][8]. - The innovative "Vitamin K3 co-production chromium green" process is expected to break the production bottleneck and improve the quality and stability of chromium green products, aligning with the growing demand in high-temperature alloy markets [8][11]. - The company is well-positioned to benefit from the increasing demand for chromium salts driven by the aerospace and military sectors, with a projected supply-demand gap of 340,900 tons by 2028 [11]. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are estimated at RMB 43.63 billion, RMB 66.42 billion, and RMB 72.52 billion, respectively, with corresponding net profits of RMB 6.04 billion, RMB 11.96 billion, and RMB 13.70 billion [11][12]. - The projected P/E ratios for the same years are 34, 17, and 15 times, reflecting a favorable valuation as the company is expected to benefit from the chromium salt market cycle [11][12]. Market Performance - The company's stock has shown significant growth, with a 12-month performance increase of 221.5%, outperforming the Shanghai and Shenzhen 300 index [5]. - As of December 31, 2025, the company's market capitalization stands at RMB 20.477 billion, with a current stock price of RMB 28.81 [5].

资料显示，浙江大洋生物科技集团股份有限公司位于浙江省杭州市建德市大洋镇朝阳路22号，成立日期 1976年1月1日，上市日期2020年10月26日，公司主营业务涉及从事无机盐、兽用原料药等化学原料产品 的生产和销售。主营业务收入构成为：无机盐产品69.91%，兽用原料药18.35%，含氟化学品7.46%，其 他产品4.28%。 从基金十大重仓股角度 数据显示，鹏华基金旗下1只基金重仓大洋生物。鹏华稳健回报混合A（009023）三季度持有股数47.16 万股，占基金净值比例为3.43%，位居第十大重仓股。根据测算，今日浮盈赚取约82.53万元。 鹏华稳健回报混合A（009023）成立日期2020年3月27日，最新规模3.27亿。今年以来收益88.14%，同 类排名190/8155；近一年收益88.14%，同类排名190/8155；成立以来收益109.01%。 1月5日，大洋生物涨5.86%，截至发稿，报31.61元/股，成交3363.97万元，换手率1.57%，总市值26.55 亿元。 鹏华稳健回报混合A（009023）基金经理为胡颖。 截至发稿，胡颖累计任职时间4年52天，现任基金资产总规模14.68亿元，任职 ...

Core Viewpoint - *ST亚太 has entered the execution phase of its restructuring plan, with significant changes in its capital structure and stock trading status [1][2][3] Group 1: Company Announcements - The Gansu Provincial Intermediate People's Court approved the restructuring plan for *ST亚太 on December 26, 2025, allowing the company to proceed with its restructuring [1] - The company will increase its total share capital from 323,270,000 shares to 484,905,000 shares through a capital reserve transfer, with the new shares allocated to attract restructuring investors [1][3] - The stock will be suspended from trading on December 31, 2025, and will resume trading on January 5, 2026, following the capital increase [1][3] Group 2: Financial Adjustments - The adjusted reference price for the stock upon resumption of trading will be set at 7.05 yuan per share, based on the closing price prior to the capital increase [1][3] - As of December 31, 2025, the restructuring investors have paid a total of 403,763,890 yuan, and the transfer of 161,635,000 shares has been completed [2] - Despite improvements in the company's fundamentals, the stock will continue to be subject to delisting risk warnings due to negative net assets at the end of 2024 [2][3]

Core Viewpoint - The December PMI indices show a significant rebound in manufacturing and non-manufacturing sectors, driven by new economic momentum and consumer goods industries, while the effects of debt reduction are easing and export resilience is supporting growth [2][3][25]. Group 1: Manufacturing Sector - The manufacturing PMI increased by 0.9 percentage points to 50.1%, marking a return to the growth threshold after nine months [2][6]. - The production and new orders indices rose by 1.7 and 1.6 percentage points to 51.7% and 50.8%, respectively [6][28]. - High-tech and equipment manufacturing sectors saw improvements, with PMIs rising by 2.4 and 0.6 percentage points to 52.5% and 50.4% [12][18]. Group 2: Consumer Goods Sector - The overall consumer goods PMI rose by 1 percentage point to 50.4%, despite a significant decline in the automotive sector PMI, which fell by 5.8 percentage points [15][25]. - The textile and apparel industry PMI increased by 4.5 percentage points to 57.5%, reflecting improvements in travel-related demand [15][25]. Group 3: Construction Sector - The construction PMI rose by 3.2 percentage points to 52.8%, indicating a recovery in building activities due to easing debt reduction pressures and the implementation of new policies [3][18]. - The new orders index in the construction sector increased by 1.3 percentage points, while the employment index slightly declined [50]. Group 4: Export and Domestic Demand - The domestic orders index rose by 1.6 percentage points to 51.1%, while the new export orders index improved by 1.4 percentage points to 49% [22][25]. - Port trade volumes increased by 0.6 percentage points year-on-year, maintaining a high level of activity [22][25].

多重正向逻辑产生共振，驱动化工行业基本面长期向好。 说一个在2025年闷声发大财，2026年仍具看点的板块！ 那就是化工，年内资金在疯狂流入，以被动ETF基金为例，2024年末全市场化工类ETF总规模仅为 25.1亿，2025年12月30日这一数值直接飙升至257亿，扩大十倍！ 化工行业在经历三年多的景气下行周期后，正迎来供需格局的实质性改善。在二级市场上也可以得到 一些印证，同花顺数据细分化工指数在2022年跌26.8%，2023年继续跌23.1%，2024年再下探3.8% 后，年内终于实现逆袭，上涨41.4%。 | 历年年度回报明细 指數名称 | 指数类型 | 2020 ÷ | 2021 ÷ | 2022 * | 2023 * | 2024 ÷ | YTD : | | --- | --- | --- | --- | --- | --- | --- | --- | | 细分化工 | 股票指数 | 51.68% | 15.72% | -26.89% | -23.17% | -3.83% | 41.40% | 作者 | Los 编辑 | 小白 （来源：Choice数据） 那是什么样的底层逻辑来推动化工行业持续上 ...